Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sirius Genomics, a developer of pharmacogenomic tests, has signed a collaboration agreement with the UK Critical Care Genomics Group or UKCCG, a collaborative consortium composed of multiple investigators, collaborators and members. Financial terms of the agreement were not disclosed.
Subscribe to our email newsletter
The agreement focuses on the continued development of Sirius’s pharmacogenomic diagnostic for responsiveness to recombinant activated Protein C (sold by Eli Lilly and company under the trademark Xigris).
Brad Popovich, president and CEO of Sirius Genomics, said: “This new collaboration with the UKCCG group will allow Sirius Genomics to significantly advance the development of our diagnostic by accessing the comprehensive database that the UKCCG group has compiled. We are delighted to be working with the UKCCG group to further our progress towards the commercialization of our first product.”